Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
BACKGROUND: Observational studies suggest that bariatric-metabolic surgery might greatly improve non-alcoholic steatohepatitis (NASH). However, the efficacy of surgery on NASH has not yet been compared with the effects of lifestyle interventions and medical therapy in a randomised trial. METHODS: ), with or without type 2 diabetes, with histologically confirmed NASH. We randomly assigned (1:1:1) participants to lifestyle modification plus best medical care, Roux-en-Y gastric bypass, or sleeve gastrectomy. The primary endpoint of the study was histological resolution of NASH without worsening of fibrosis at 1-year follow-up. This study is registered at ClinicalTrials.gov, NCT03524365. FINDINGS: Between April 15, 2019, and June 21, 2021, we biopsy screened 431 participants; of these, 103 (24%) did not have histological NASH and 40 (9%) declined to participate. We randomly assigned 288 (67%) participants with biopsy-proven NASH to lifestyle modification plus best medical care (n=96 [33%]), Roux-en-Y gastric bypass (n=96 [33%]), or sleeve gastrectomy (n=96 [33%]). In the intention-to-treat analysis, the percentage of participants who met the primary endpoint was significantly higher in the Roux-en-Y gastric bypass group (54 [56%]) and sleeve gastrectomy group (55 [57%]) compared with lifestyle modification (15 [16%]; p<0·0001). The calculated probability of NASH resolution was 3·60 times greater (95% CI 2·19-5·92; p<0·0001) in the Roux-en-Y gastric bypass group and 3·67 times greater (2·23-6·02; p<0·0001) in the sleeve gastrectomy group compared with in the lifestyle modification group. In the per protocol analysis (236 [82%] participants who completed the trial), the primary endpoint was met in 54 (70%) of 77 participants in the Roux-en-Y gastric bypass group and 55 (70%) of 79 participants in the sleeve gastrectomy group, compared with 15 (19%) of 80 in the lifestyle modification group (p<0·0001). No deaths or life-threatening complications were reported in this study. Severe adverse events occurred in ten (6%) participants who had bariatric-metabolic surgery, but these participants did not require re-operations and severe adverse events were resolved with medical or endoscopic management. INTERPRETATION: Bariatric-metabolic surgery is more effective than lifestyle interventions and optimised medical therapy in the treatment of NASH. FUNDING: Fondazione Policlinico Universitario A Gemelli, Policlinico Universitario Umberto I and S Camillo Hospital, Rome, Italy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a landmark prospective trial, Verrastro and colleagues demonstrated that one year following RYGB surgery, resolution of non-alcoholic steatohepatitis (NASH) without progression of fibrosis occurred in 56% of patients compared to only 16% in patients managed by lifestyle modifications alone (p < 0.0001) [28].”
From Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review (2025) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The BRAVES multicentre, open-label, randomised study demonstrated histological resolution of MASH without worsening of fi brosis in 55% of those assigned to Roux-en-Y gastric bypass or sleeve gastrectomy at 1-year follow-up vs. 15% in the lifestyle modi fi cation group in the intention-to-treat analysis.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [444]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Bariatric surgery achieves greater and more sustainable weight reduction than lifestyle approaches [82], which was recently confirmed in a first RCT comparing lifestyle modification plus optimized pharmacological therapy with Roux-en-Y gastric bypass and sleeve gastrectomy [83].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [83]
The cited source says what the claim attributes to it.
In the citing paper
“In this RCT, about 6% of participants had severe adverse events related to surgery.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [444]
The cited source says what the claim attributes to it.
In the citing paper
“In this open-label RCT, fi brosis improvement by > -1 stage without worsening of MASH after 1 year was achieved in 37% and 39% of patients after Roux-en-Y gastric bypass and sleeve gastrectomy, respectively, vs. 23% after lifestyle modi fi cation.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [444]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 33 · Cited by 362
Research works printed but not linked: 1
- Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021 · DOI · Paper page
Metadata
- Authors
- Verrastro, O., Panunzi, S., Castagneto-Gissey, L., De Gaetano, A., Lembo, E., Capristo, E., Guidone, C., Angelini, G., Pennestrì, F., Sessa, L., Vecchio, F. M., Riccardi, L., Zocco, M. A., Boskoski, I., Casella-Mariolo, J. R., Marini, P., Pompili, M., Casella, G., Fiori, E., Rubino, F., Bornstein, S. R., Raffaelli, M., & Mingrone, G.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- National Research Council (IT)
- Agostino Gemelli University Polyclinic (IT)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Sapienza University of Rome (IT)
- King's College London (GB)
- Corresponding author
- Mingrone, Geltrude
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2023-05
- Volume
- 401
- Issue
- 10390
- Pages
- 1786-1797
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4366692639
- Semantic Scholar
- de28f8edbcd21608a40c95d22d97d847e1453ffa
- Cited by
- 362
- References
- 33
- Citations by year
- 2026: 98 · 2025: 107 · 2024: 116 · 2023: 41
- FWCI
- 96.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- The Lancet (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Surgery › Minimally Invasive Surgical Techniques
- Keywords
- nonalcoholic steatohepatitis, bariatric metabolic surgery, Roux-en-Y gastric bypass, sleeve gastrectomy, lifestyle modification, liver fibrosis, type 2 diabetes, obesity, weight loss, liver biopsy histology
- MeSH terms
- Diabetes Mellitus, Type 2, Gastrectomy, Humans, Life Style, Obesity, Morbid, Laparoscopy, Gastric Bypass, Treatment Outcome, Bariatric Surgery, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(23)00634-7
- The paper
- Verrastro, O., Panunzi, S., Castagneto-Gissey, L., De Gaetano, A., Lembo, E., Capristo, E., Guidone, C., Angelini, G., Pennestrì, F., Sessa, L., Vecchio, F. M., Riccardi, L., Zocco, M. A., Boskoski, I., Casella-Mariolo, J. R., Marini, P., Pompili, M., Casella, G., Fiori, E., . . . Mingrone, G. (2023). Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(23)00634-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.